The safety profile of fingolimod is well estab- lished in clinical trials and post-marketing studies. This study aimed to evaluate the safety and tolerability of fin- golimod in a cohort of Italian patients with relapsing- remitting multiple sclerosis (RRMS). This is a non-com- parative, open-label, multicentre, interventional study conducted in patients with RRMS with no suitable alter- native treatment option. Safety and tolerability of fin- golimod 0.5 mg were assessed by recording adverse events (AEs) and serious AEs (SAEs). Of the 906 patients enrolled in the study, 91 % of the patients completed the study. AEs and SAEs were reported in 35.4 and 2.9 % of the patients, respectively. Most common AEs reported were headache (4.1 %), influenza (2.1 %), lymphopenia (1.8 %), asthenia (1.8 %) and pyrexia (1.8 %). Increased alanine aminotransferase levels and hypertension were reported as AE in 1.0 and 1.4 % of the patients, respec- tively. Macular oedema was reported in three patients. These results emphasize the safety of fingolimod in patients representing the real-world clinical practice in the Italian population. Fingolimod was safe and well tolerated in this population, which, compared to those enrolled in pivotal trials in terms of concomitant diseases and used medications, is broader. Trial registration: EudraCT 2011-000770-60.

Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy / Laroni, Alice; Brogi, Davide; Brescia Morra, Vincenzo; Guidi, Leonello; Pozzilli, Carlo; Comi, Giancarlo; Lugaresi, Alessandra; Turrini, Renato; Raimondi, Debora; Uccelli, Antonio; Mancardi, Giovanni Luigi. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - 38:1(2017), pp. 53-59. [10.1007/s10072-016-2701-z]

Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy

Pozzilli, Carlo;
2017

Abstract

The safety profile of fingolimod is well estab- lished in clinical trials and post-marketing studies. This study aimed to evaluate the safety and tolerability of fin- golimod in a cohort of Italian patients with relapsing- remitting multiple sclerosis (RRMS). This is a non-com- parative, open-label, multicentre, interventional study conducted in patients with RRMS with no suitable alter- native treatment option. Safety and tolerability of fin- golimod 0.5 mg were assessed by recording adverse events (AEs) and serious AEs (SAEs). Of the 906 patients enrolled in the study, 91 % of the patients completed the study. AEs and SAEs were reported in 35.4 and 2.9 % of the patients, respectively. Most common AEs reported were headache (4.1 %), influenza (2.1 %), lymphopenia (1.8 %), asthenia (1.8 %) and pyrexia (1.8 %). Increased alanine aminotransferase levels and hypertension were reported as AE in 1.0 and 1.4 % of the patients, respec- tively. Macular oedema was reported in three patients. These results emphasize the safety of fingolimod in patients representing the real-world clinical practice in the Italian population. Fingolimod was safe and well tolerated in this population, which, compared to those enrolled in pivotal trials in terms of concomitant diseases and used medications, is broader. Trial registration: EudraCT 2011-000770-60.
2017
Fingolimod; Relapsing-remitting multiple sclerosis; Safety; Tolerability; Adult; Female; Fingolimod Hydrochloride; Headache; Humans; Immunosuppressive Agents; Infection; Italy; Macular Edema; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome; 2708; Neurology (clinical); Psychiatry and Mental Health
01 Pubblicazione su rivista::01a Articolo in rivista
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy / Laroni, Alice; Brogi, Davide; Brescia Morra, Vincenzo; Guidi, Leonello; Pozzilli, Carlo; Comi, Giancarlo; Lugaresi, Alessandra; Turrini, Renato; Raimondi, Debora; Uccelli, Antonio; Mancardi, Giovanni Luigi. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - 38:1(2017), pp. 53-59. [10.1007/s10072-016-2701-z]
File allegati a questo prodotto
File Dimensione Formato  
Laroni_Safety and tolerability_2016.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 420.24 kB
Formato Adobe PDF
420.24 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1081768
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 24
social impact